Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LEGN 
Legend Biotech Corp (LEGN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: LEGN (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
22 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $77.46
1 Year Target Price $77.46
| 11 | Strong Buy |
| 10 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -4.65% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 6.34B USD | Price to earnings Ratio - | 1Y Target Price 77.46 |
Price to earnings Ratio - | 1Y Target Price 77.46 | ||
Volume (30-day avg) 22 | Beta 0.28 | 52 Weeks Range 27.34 - 51.77 | Updated Date 09/17/2025 |
52 Weeks Range 27.34 - 51.77 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.78 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -40.83% | Operating Margin (TTM) -8.58% |
Management Effectiveness
Return on Assets (TTM) -7.81% | Return on Equity (TTM) -29.65% |
Valuation
Trailing PE - | Forward PE 20.41 | Enterprise Value 5673612468 | Price to Sales(TTM) 7.95 |
Enterprise Value 5673612468 | Price to Sales(TTM) 7.95 | ||
Enterprise Value to Revenue 7.12 | Enterprise Value to EBITDA -15.34 | Shares Outstanding 184571008 | Shares Floating 162765522 |
Shares Outstanding 184571008 | Shares Floating 162765522 | ||
Percent Insiders 1.3 | Percent Institutions 47.49 |
Upturn AI SWOT
Legend Biotech Corp
Company Overview
History and Background
Legend Biotech Corp. was founded in 2014. It is a global biotechnology company developing, manufacturing, and commercializing novel cell therapies for oncology and other indications.
Core Business Areas
- Cell Therapy Development and Manufacturing: Focuses on developing and manufacturing cell therapies, primarily CAR-T cell therapies, for cancer treatment.
- Research and Development: Engages in research and development to discover and advance novel therapeutic candidates.
- Commercialization: Commercializes approved cell therapies, starting with CARVYKTIu00ae for multiple myeloma.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The company has a structured organizational hierarchy with departments focused on research, development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- CARVYKTIu00ae (ciltacabtagene autoleucel): CARVYKTI is a BCMA-directed CAR-T cell therapy approved for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Legend Biotech co-developed and co-commercializes CARVYKTI with Janssen Biotech, Inc. Competitors include Bristol Myers Squibb (BMS) with Abecma (idecabtagene vicleucel).
Market Dynamics
Industry Overview
The cell therapy market is rapidly growing, driven by advancements in immunotherapy and the increasing prevalence of cancer. CAR-T cell therapies are a significant part of this market.
Positioning
Legend Biotech is a key player in the cell therapy space, particularly in CAR-T cell therapy for multiple myeloma. Its co-development and commercialization agreement with Janssen enhances its competitive position.
Total Addressable Market (TAM)
The TAM for CAR-T cell therapies for multiple myeloma is estimated to be in the billions of dollars. Legend Biotech is well-positioned to capture a significant portion of this market with CARVYKTI.
Upturn SWOT Analysis
Strengths
- Innovative CAR-T cell therapy platform
- Strategic partnership with Janssen
- Strong clinical trial results for CARVYKTI
- Established manufacturing capabilities
Weaknesses
- Reliance on a single marketed product (CARVYKTI)
- High cost of goods sold (COGS) for cell therapies
- Competition from other CAR-T cell therapies
- Manufacturing complexity of CAR-T therapies
Opportunities
- Expansion of CARVYKTI label to earlier lines of therapy
- Development of new CAR-T cell therapies for other cancer types
- Potential for strategic collaborations and acquisitions
- Expansion into new geographic markets
Threats
- Regulatory hurdles and changing reimbursement landscape
- Competition from biosimilars and generics
- Adverse events or safety concerns with CAR-T cell therapies
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- BMY
Competitive Landscape
Legend Biotech has a strong partnership with Janssen, giving it access to their commercialization infrastructure. It's CAR-T product is innovative, but manufacturing and reimbursement are key challenges, as they are for all CAR-T products. Bristol Myers Squibb is a major competitor.
Growth Trajectory and Initiatives
Historical Growth: Significant revenue growth in recent years due to the launch and increasing adoption of CARVYKTI.
Future Projections: Analysts project continued strong revenue growth for CARVYKTI and expansion into new indications. Focus on increasing manufacturing capacity and driving product adoption.
Recent Initiatives: Focus on expanding manufacturing capacity for CARVYKTI to meet demand, conducting clinical trials to expand the label of CARVYKTI, and advancing earlier stage pipeline programs.
Summary
Legend Biotech is a promising company in the cell therapy space, particularly with its CAR-T therapy, CARVYKTI. The partnership with Janssen provides a strong commercial foundation. However, challenges remain in manufacturing, competition, and the high cost of cell therapies. The company needs to expand their product offerings beyond CARVYKTI.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a financial advisor before making investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Legend Biotech Corp
Exchange NASDAQ | Headquaters Somerset, NJ, United States | ||
IPO Launch date 2020-06-05 | CEO & Director Dr. Ying Huang Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 2800 | Website https://www.legendbiotech.com |
Full time employees 2800 | Website https://www.legendbiotech.com | ||
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma (NHL), acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. The company was founded in 2014 and is headquartered in Somerset, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.